192 related articles for article (PubMed ID: 1088369)
1. On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression.
Amamoto T; Sarai K
Hiroshima J Med Sci; 1976 Sep; 25(2-3):135-40. PubMed ID: 1088369
[No Abstract] [Full Text] [Related]
2. [Urinary excretion of 5-hydroxyindoleacetic acid and serum tryptophan and serotonin levels in patients with depression].
Pietruszewska I; Jasińska M; Lewicka-Wysocka H; Marcjan K; Stencka K
Psychiatr Pol; 1984; 18(1):9-16. PubMed ID: 6204348
[No Abstract] [Full Text] [Related]
3. [Cerebral and peripheral consumption of L-5-HTP in patients with manic, depressive or psychotic syndromes].
Gaillard JM; Eisenring JJ; Tissot R
Encephale; 1973; 62(5):395-407. PubMed ID: 4546593
[No Abstract] [Full Text] [Related]
4. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients.
Takahashi S; Takahashi R; Masumura I; Miike A
Folia Psychiatr Neurol Jpn; 1976; 30(4):461-73. PubMed ID: 1087913
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of homovanillic acid, 5-hydroxyindoleacetic acid and cortisol, and serotonin turnover in depressed patients.
Mitani H; Shirayama Y; Yamada T; Kawahara R
Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):531-4. PubMed ID: 16414168
[TBL] [Abstract][Full Text] [Related]
6. Depression: new evidence in support of biological differentiation.
Garfinkel PE; Warsh JJ; Stancer HC
Am J Psychiatry; 1979 Apr; 136(4B):535-9. PubMed ID: 426139
[TBL] [Abstract][Full Text] [Related]
7. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron.
Castejon AM; Paez X; Hernandez L; Cubeddu LX
J Pharmacol Exp Ther; 1999 Dec; 291(3):960-6. PubMed ID: 10565811
[TBL] [Abstract][Full Text] [Related]
8. Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury.
Christofides J; Bridel M; Egerton M; Mackay GM; Forrest CM; Stoy N; Darlington LG; Stone TW
J Neurochem; 2006 May; 97(4):1078-88. PubMed ID: 16573644
[TBL] [Abstract][Full Text] [Related]
9. Serotonin metabolism in patients with carcinoid tumors: incidence of 5-hydroxytryptophan-secreting tumors.
Feldman JM
Gastroenterology; 1978 Dec; 75(6):1109-14. PubMed ID: 309417
[TBL] [Abstract][Full Text] [Related]
10. Serotonergic disturbances in autistic disorder: L-5-hydroxytryptophan administration to autistic youngsters increases the blood concentrations of serotonin in patients but not in controls.
Croonenberghs J; Verkerk R; Scharpe S; Deboutte D; Maes M
Life Sci; 2005 Mar; 76(19):2171-83. PubMed ID: 15733932
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of 5-hydroxyindole derivates after administration of L-5-hydroxytryptophan ethyl ester.
Korf J; Sebens JB; Venema K; van Praag HM
Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):171-82. PubMed ID: 968174
[TBL] [Abstract][Full Text] [Related]
12. Urinary excretion of 5-hydroxyindoleacetic acid, serotonin and 6-sulphatoxymelatonin in normoserotonemic and hyperserotonemic autistic individuals.
Mulder EJ; Anderson GM; Kemperman RF; Oosterloo-Duinkerken A; Minderaa RB; Kema IP
Neuropsychobiology; 2010; 61(1):27-32. PubMed ID: 19923863
[TBL] [Abstract][Full Text] [Related]
13. Comparison of L-5-hydroxytryptophan and L-5-hydroxytryptophan inosinate as agents for increasing brain serotonin formation in rats.
Fuller RW; Snoddy HD; Robertson DW
Res Commun Chem Pathol Pharmacol; 1992 Apr; 76(1):121-4. PubMed ID: 1381513
[TBL] [Abstract][Full Text] [Related]
14. Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man.
Magnussen I; Jensen TS; Rand JH; Van Woert MH
Acta Pharmacol Toxicol (Copenh); 1981 Sep; 49(3):184-9. PubMed ID: 6175178
[TBL] [Abstract][Full Text] [Related]
15. Blood serotonin (5-HT) level and 24 hrs urinary excretion of 5-hydroxyindoleacetic acid (5-HIAA) in patients with active liver cirrhosis and in patients with hepatic encephalopathy.
Słomka M; Skrzydło-Radomańska B; Celiński K
Ann Univ Mariae Curie Sklodowska Med; 1991; 46():75-80. PubMed ID: 1285400
[No Abstract] [Full Text] [Related]
16. Plasma 5-hydroxytryptamine (5-HT) in migraine during an attack-free period.
Nagata E; Shibata M; Hamada J; Shimizu T; Katoh Y; Gotoh K; Suzuki N
Headache; 2006 Apr; 46(4):592-6. PubMed ID: 16643553
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and biochemical contributions on the action of maprotiline and clomipramine in depressive states (preliminary observation)].
Ravizza L
Psychiatr Clin (Basel); 1979; 13(3):164-72. PubMed ID: 93762
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of intraplatelet and urinary 5-hydroxytryptamine (5-HT), and urinary 5-hydroxyindoleacetic acid (5-HIAA) levels in patients with toxemia of pregnancy.
Ishii Y; Kanai H; Maezawa A; Tsuchida A; Yano S; Naruse T
Res Commun Chem Pathol Pharmacol; 1993 Apr; 80(1):21-40. PubMed ID: 7683821
[TBL] [Abstract][Full Text] [Related]
19. [Changes of plasma serotonin precursor metabolite concentrations in postmenopausal women with hot flushes].
Chen Y; Lü X; Huang Y; Xin X; Ye X
Zhonghua Fu Chan Ke Za Zhi; 2002 Dec; 37(12):726-8. PubMed ID: 12622915
[TBL] [Abstract][Full Text] [Related]
20. Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5-hydroxytryptophan intake.
Joy T; Walsh G; Tokmakejian S; Van Uum SH
Can J Gastroenterol; 2008 Jan; 22(1):49-53. PubMed ID: 18209781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
